{"schema_version":"1.0","hypothesis_id":38641,"triple":{"drug":"tofacitinib","drug_canonical":"tofacitinib","mediator":"JAK/STAT pathway","mediator_canonical":"jak/stat pathway","outcome":"post-operative recurrence","outcome_canonical":"post-operative recurrence"},"domain":{"domain":"cross_domain","source":"rheumatoid_arthritis","target":"inflammatory_bowel_disease"},"provenance_completeness":"partial_backfill","completeness_notes":"Backfilled retroactively from DB state on 2026-05-13. The pipeline_run this row references was created by the backfill script, not by the actual generation orchestrator. Source papers, claims, scoring, and embedding config are recovered; generation-time metadata (exact git commit at gen time, host, exact command) is not recoverable.","source_papers":[{"doi":"10.4103/idoj.idoj_328_25","pmid":"41834310","year":2026,"roles":["drug_mediator"],"title":"De novo Generalized Pustular Psoriasis: A Tofacitinib-Induced Paradoxical Adverse Event","journal":"Indian Dermatol Online J","work_id":300440,"publication_date":"2026-03-16"},{"doi":"10.1016/j.intimp.2025.115135","pmid":"40614601","year":2025,"roles":["drug_mediator"],"title":"Old drugs with new applications: Tofacitinib-mediated inhibition of M1-like macrophage polarization in acute pancreatitis by the JAK/STAT and emerging NOD-like receptor pathways","journal":"Int Immunopharmacol","work_id":299131,"publication_date":"2025-07-03"},{"doi":"10.2147/ccid.s470170","pmid":"39220289","year":2024,"roles":["drug_mediator"],"title":"Tofacitinib for Pityriasis Rubra Pilaris: A Case Report","journal":"Clin Cosmet Investig Dermatol","work_id":298385,"publication_date":"2024-08-01"},{"doi":"10.1111/1756-185x.14810","pmid":"37395471","year":2023,"roles":["drug_mediator"],"title":"Tofacitinib in pyoderma gangrenosum – A case series","journal":"Int J Rheum Dis","work_id":293043,"publication_date":"2023-07-03"},{"doi":"10.1093/ecco-jcc/jjac021","pmid":"35143619","year":2022,"roles":["mediator_outcome"],"title":"Identification of Gene Expression Profiles Associated with an Increased Risk of Post-Operative Recurrence in Crohn’s Disease","journal":"J Crohns Colitis","work_id":270264,"publication_date":"2022-02-02"},{"doi":"10.34172/aim.2021.52","pmid":"34196200","year":2021,"roles":["drug_mediator"],"title":"Efficacy and Safety of Tofacitinib for Treatment of Moderate to Severe Active Ulcerative Colitis: First Report from Iran","journal":"Arch Iran Med","work_id":303293,"publication_date":"2021-05-01"},{"doi":"10.46497/archrheumatol.2020.7568","pmid":"33458657","year":2020,"roles":["drug_mediator"],"title":"The Effects of Tofacitinib-Mediated Janus Kinase/Signal Transducers and Activators of the Transcription Signal Pathway Inhibition on Collagen Biosynthesis in Hepatic and Skin Fibroblast Cell Culture","journal":"Arch Rheumatol","work_id":298805,"publication_date":"2020-09-24"},{"doi":"10.1177/2397198319865367","pmid":"35382402","year":2019,"roles":["drug_mediator"],"title":"The JAK/STAT pathway is activated in systemic sclerosis and is effectively targeted by tofacitinib","journal":"J Scleroderma Relat Disord","work_id":286370,"publication_date":"2019-08-07"}],"source_paper_count":8,"extracted_claims":[{"side":"drug_mediator","object":"JAK/STAT pathway","context":"in bleomycin-induced fibrosis mouse model and TSK1/+ mice","subject":"tofacitinib","work_id":286370,"claim_id":207107,"polarity":"positive","predicate":"inhibits","confidence":0.9,"extraction_run_id":29},{"side":"drug_mediator","object":"JAK/STAT pathway","context":"in pyoderma gangrenosum patients","subject":"Tofacitinib","work_id":293043,"claim_id":232612,"polarity":"positive","predicate":"inhibits","confidence":1.0,"extraction_run_id":29},{"side":"drug_mediator","object":"JAK/STAT pathway","context":"in the treatment of pityriasis rubra pilaris","subject":"tofacitinib","work_id":298385,"claim_id":249704,"polarity":"positive","predicate":"inhibits","confidence":0.6,"extraction_run_id":29},{"side":"drug_mediator","object":"JAK/STAT pathway","context":"in hepatic and skin fibroblast cell culture","subject":"tofacitinib","work_id":298805,"claim_id":251091,"polarity":"positive","predicate":"inhibits","confidence":0.9,"extraction_run_id":29},{"side":"drug_mediator","object":"JAK/STAT pathway","context":"in AP models, reducing p-STAT1 and p-STAT3","subject":"Tofacitinib","work_id":299131,"claim_id":252175,"polarity":"positive","predicate":"inhibits","confidence":0.95,"extraction_run_id":29},{"side":"drug_mediator","object":"JAK/STAT pathway","context":"as a mechanism","subject":"Tofacitinib","work_id":300440,"claim_id":256364,"polarity":"positive","predicate":"inhibits","confidence":0.9,"extraction_run_id":29},{"side":"drug_mediator","object":"JAK/STAT pathway","context":"in active ulcerative colitis","subject":"Tofacitinib","work_id":303293,"claim_id":264195,"polarity":"positive","predicate":"inhibits","confidence":0.9,"extraction_run_id":29},{"side":"mediator_outcome","object":"post-operative recurrence","context":"at the ileal margin in Crohn's disease","subject":"JAK/STAT pathway","work_id":270264,"claim_id":221761,"polarity":"positive","predicate":"predicts","confidence":0.75,"extraction_run_id":31}],"extracted_claim_count":8,"extraction":{"model":"deepseek-v4-flash","model_source":"configured","prompt_version":"v1_2026_05_07","run_ids":[29,31]},"bridge":{"a_to_b_predicate":"inhibits","b_to_c_predicate":"predicts","a_to_b_evidence_count":7,"b_to_c_evidence_count":1,"edge_support_log_ab":2.0794415416798357,"edge_support_log_bc":0.6931471805599453,"novelty_factor":1.0,"direct_a_to_c_count":0},"embedding":{"model":"bge-m3","dim":1024,"max_length":8192,"similarity_scores":{}},"scoring":{"method":"swanson_abc_log_evidence_with_novelty_penalty","formula":"score = min((log(ab+1) + log(bc+1)) * novelty / 10, 1.0); novelty = 1.0 if direct==0 else 0.7 / (direct+1)","score_raw":0.2772588722239781,"score":0.2772588722239781,"quality_tier":"high","quality_reason":null},"pipeline_run":{"id":4,"run_uuid":"eb8b7730-d92e-4cd5-95dd-95f6c5d62cc2","command":"scripts/backfill_provenance_v2.py:v2_2026_05_12","status":"completed","git_commit":"9996ffaa56e9b7cd5f677bd8203624c2c18aa000","host":"MacBook-Pro-Daniel96.local","started_at":"2026-05-12T21:35:53.363326+00:00","ended_at":"2026-05-12T21:43:41.903387+00:00","notes":"Retroactive provenance backfill on 2026-05-13 for snapshot v2_2026_05_12. Synthetic pipeline_runs row — original generation run records are lost (pre-date provenance schema). All recoverable fields populated from current DB state (claims, works, repurposing_hypotheses); pipeline_run record is synthetic, hence completeness='partial_backfill'.\nBackfilled 1,618 provenance rows. Source papers: avg=3.73, zero=0. Claims matched: avg=4.09, zero=0.\nRefreshed 1,618 provenance rows. Source papers: avg=3.73, zero=0. Claims matched: avg=4.09, zero=0.\nRefreshed 1,618 provenance rows. Source papers: avg=3.73, zero=0. Claims matched: avg=4.09, zero=0.","domains":["als","alzheimer","depression","epilepsy","glioblastoma","inflammatory_bowel_disease","multiple_sclerosis","pancreatic_cancer","rheumatoid_arthritis","type_2_diabetes"]},"generated_at":"2026-05-12T21:43:40.945575+00:00"}